Previous 10 | Next 10 |
Farmer Brothers Company (FARM) is expected to report $-0.61 for Q4 2023 Aspen Group Inc. (ASPU) is expected to report for Q1 2023 Kaspien Holdings Inc. (KSPN) is expected to report for Q1 2024 AGC Inc ADR (ASGLY) is expected to report for Q2 2023 Shimano Inc. ADR (SMNNY) is expect...
Alzamend Neuro Inc. (ALZN) is expected to report for quarter end 2023-07-31
Safety aspects of AL001 development may qualify for (505)(b)(2) pathway for FDA approval Alzamend’s recently completed a Phase IIA Study of AL001 in Alzheimer’s and healthy patients that identified a candidate dose that is unlikely to require therapeutic drug monitor...
Topline data identifies maximum tolerated dose from Phase IIA multiple ascending dose study as assessed by an independent safety review committee Identified dose is unlikely to require lithium therapeutic drug monitoring Alzamend plans two Phase II clinical trials ...
Panel to be held on Tuesday, June 20, 2023 at 2:00 PM ET Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer ...
2023-05-24 08:00:21 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of ...
2023-05-11 12:38:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it’s not particularly likely to happen. Indeed, such an endeavor requires a...
Ault Alliance Congratulates Alzamend Neuro on This Important and Historic Milestone in Clinical Drug Discovery and Development Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“ Ault Alliance ” or the “ Company ”), is prou...
2023-04-03 09:09:47 ET Alzamend Neuro ( NASDAQ: ALZN ) has started a phase 1/2a trial of ALZN002, an immunotherapy vaccine for mild to moderate Alzheimer's dementia. The trial, which will enroll 20-30 participants, will evaluate the safety, tolerability, and efficacy of AL...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder, major depressive disorder (“MDD...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...